Vertex Pharmaceuticals Financial Indicators Patterns

VRTX -- USA Stock  

Earning Report: October 23, 2019  

We advise you to exercise Vertex Pharmaceuticals fundamental analysis to see if markets are presently mispricing the corporation. In other words this interface allows you to confirm available indicators of Vertex Pharmaceuticals as well as the relationship between them. We found thirty-six available drivers for Vertex Pharmaceuticals Incorpor which can be compared to its competition. To make sure the equity is not overpriced, please validate all Vertex Pharmaceuticals fundamentals including its Total Debt, Earnings Per Share and the relationship between Net Income and Book Value Per Share . Given that Vertex Pharmaceuticals has Number of Shares Shorted of 4.44 M, we advise you double-check Vertex Pharmaceuticals Incorpor current market performance to make sure the company can sustain itself down the road. Use Vertex Pharmaceuticals to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Vertex Pharmaceuticals to be traded at $195.49 in 30 days.

Chance of Financial Distress

Vertex Pharmaceuticals Incorpor has less than 1 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Vertex Pharmaceuticals Company Summary

Vertex Pharmaceuticals competes with Dr Reddys, Zoetis, Perrigo Company, and Regeneron Pharmaceuticals. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.

Vertex Pharmaceuticals Price to Sales vs Debt to Equity

Vertex Pharmaceuticals Incorpor is rated below average in price to sales category among related companies. It is rated below average in debt to equity category among related companies fabricating about  0.98  of Debt to Equity per Price to Sales. The ratio of Price to Sales to Debt to Equity for Vertex Pharmaceuticals Incorpor is roughly  1.02 

Vertex Pharmaceuticals Systematic Risk

The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Vertex Pharmaceuticals correlated with the market. If Beta is less than 0 Vertex Pharmaceuticals generally moves in the opposite direction as compared to the market. If Vertex Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vertex Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vertex Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Vertex Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Vertex Pharmaceuticals Thematic Clasifications

Biotech Idea

Vertex Pharmaceuticals October 20, 2019 Opportunity Range

Also please take a look at World Market Map. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.